NIH Funds Study of Fully Personalized Immunotherapy AGS-004 Combined With a Latency Reversing Therapy for the Treatment of HIV
Eliminating the latent virus reservoir has been shown to be an essential goal in efforts to eradicate HIV. Research has shown that histone deacetylase (HDAC) inhibitors can activate cells that are latently infected with HIV, making them more visible to the immune system. One strategy to achieve HIV eradication is known as the "kick and kill" approach where a latency reversing therapy such as an HDAC inhibitor is combined with an immunotherapy to maximize the immune system's response to the latent reservoir in an effort to eliminate it.
"Previous study results suggest AGS-004 can induce anti-viral memory T-cell responses that are associated with lower persistent viral reservoirs when administered in combination with standard antiretroviral therapy (ART)," said Dr.
"With this NIH funding, we can now study whether combining AGS-004 treatment with a latent reservoir mobilizer can lead to the elimination of HIV-infected cells," stated Dr.
About the Arcelis® Technology Platform
Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease specific antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.
Forward Looking Statements
Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the
CONTACT: Media contact:
Adam DaleyBerry & Company Public Relations 212-253-8881 firstname.lastname@example.org Investor contact: Nancy Yu Burns McClellanNyu@burnsmc.com 212-213-0006
News Provided by Acquire Media